In this way, our work presents in vitro, ex vivo, and in vivo evidence of how BIRC3-deletion and/or mutation in the remaining allele of del(11q) cells contributes to NF-κB signaling activation, CLL progression, and therapy response. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.